Asterias Biotherapeutics (AST) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
Tweet
Share
E-mailGet Alerts AST Hot Sheet
Join SI Premium – FREE
Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $608 thousand versus the consensus estimate of $1.07 million.
For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why Ed Yardeni says the best market entry points are still to come
- Genius Sports Ltd. (GENI) PT Lowered to $7 at Stifel on Lower Media Content
- Business First Bancshares, Inc. (BFST) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
